Blog: FLT3-ITD Detection Tech Note

Published Fri Sep 8, 2017


Internal tandem duplications (ITDs) in the FLT3 gene are detected in about 25% of acute myeloid leukemia (AML) samples and are associated with a poor prognosis. Furthermore, FLT3-ITD expressed kinases are sensitive to tyrosine kinase inhibitors, making them a target of interest for the development of novel AML treatments. However, detecting FLT3-ITDs from NGS data, alongside other mutation types common in AML, can be challenging.

ArcherDX scientists developed Archer® VariantPlex® myeloid assays to detect FLT3-ITDs, along with other myeloid-specific variants, by targeted next-generation sequencing (NGS). A new technical note discusses how Anchored Multiplex PCR (AMP™) chemistry in conjunction with the data-optimized analysis algorithm in Archer Analysis enable accurate detection of FLT3-ITDs across all sizes and insertion sites from clinical-type samples. The table below shows that FLT3-ITDs were detected in AML-positive blood and bone marrow samples with 100% accuracy using these VariantPlex assays.

FLT3-ITDs were detected in AML-positive blood and bone marrow samples with 100% accuracy using Archer® VariantPlex assays..

Download the tech note for more details and data.

FLT3-ITD AMP tech note

Want more information about Archer's VariantPlex® Myeloid NGS assays?

Click here

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.